COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION

被引：0
|
作者：
McEwan, P. [1 ]
Darlington, O. [1 ]
Bergenheim, K. [2 ]
Qin, L. [3 ]
机构：
[1] Hlth Econ & Outcomes Res Ltd, Cardiff, Wales
[2] AstraZeneca, Gothenburg O, Sweden
[3] AstraZeneca, Gaithersburg, MD USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV45
引用
收藏
页码：S494 / S494
页数：1
相关论文
共 50 条
  • [21] THE COST EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN KOREA
    Lee, J.
    Ko, S.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A617 - A618
  • [22] Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction
    Arbel, Ronen
    Azab, Abed N.
    Oberoi, Mansi
    Aboalhasan, Enis
    Star, Artyom
    Elhaj, Khaled
    Khalil, Fouad
    Alnsasra, Hilmi
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [23] DAPAGLIFLOZIN VERSUS SACUBITRIL-VALSARTAN FOR HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION
    Arbel, Ronen
    Oberoi, Mansi
    Alnsasra, Hilmi
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 628 - 628
  • [24] Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective
    Chin, Ken Lee
    Zomer, Ella
    Wang, Bing H.
    Liew, Danny
    [J]. HEART LUNG AND CIRCULATION, 2020, 29 (09): : 1310 - 1317
  • [25] Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
    Mariano A. Giorgi
    Carlos P. Boissonnet
    Paula Soledad Luque
    Jimena Piastrella
    Carlos Porley
    Fernanda Ditata
    Sergio Volman
    [J]. Health Economics Review, 13
  • [26] Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction
    King, Jordan
    Bress, Adam
    Bellows, Brandon
    [J]. ANNALS OF INTERNAL MEDICINE, 2017, 166 (08) : 606 - 607
  • [27] Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
    Giorgi, Mariano A.
    Boissonnet, Carlos P.
    Luque, Paula Soledad
    Piastrella, Jimena
    Porley, Carlos
    Ditata, Fernanda
    Volman, Sergio
    [J]. HEALTH ECONOMICS REVIEW, 2023, 13 (01)
  • [28] Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
    Gaziano, Thomas A.
    Fonarow, Gregg C.
    Claggett, Brian
    Chan, Wing W.
    Deschaseaux-Voinet, Celine
    Turner, Stuart J.
    Rouleau, Jean L.
    Zile, Michael R.
    McMurray, John J. V.
    Solomon, Scott D.
    [J]. JAMA CARDIOLOGY, 2016, 1 (06) : 666 - 672
  • [29] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH REDUCED EJECTION FRACTION PATIENTS IN INDIAN HEALTHCARE SETTING
    Gokhale, S.
    Partha, G.
    Proudfoot, C.
    Anand, S.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S115 - S115
  • [30] Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context
    D'Angiolella, Lucia S.
    Cortesi, Paolo A.
    Pitotti, Claudia
    Ritrovato, Daniela
    Mantovani, Lorenzo G.
    Senni, Michele
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (11) : 1551 - 1553
12345